Hello am I Missing something here we have IMO great news.
We have just been told that SNTA is going use Crizotinib, a Pfizier drug. Going to trial evaluating the combination of ganetespib and crizotinib in ALK+ NSCLC patients is expected to initiate shortly. ))))
Below I have posted the about Crizotinib
FDA Approval for Crizotinib
Brand name: Xalkori®
On August 26, 2011, the Food and Drug Administration (FDA) granted accelerated approval to crizotinib (Xalkori Capsules, made by Pfizer, Inc.) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.
combination of ganetespib and crizotinib in ALK+ NSCLC patients is expected to initiate shortly. ))))
Already Crizotinib is FDA appproved. Now they are going to use our DRUG ganetespib and combine the two. Once again am I missing something here, IMO I believe this could be HUGE.
Someone said awhile ago Hm is Pfizier Looking at SNTA. Wow is 1 plus 1, 2
Always do as you feel, Not what you hear
Hit post button a bit too soon.
Yes, if Synta went over $5 before I sold the options and stayed that way through March 17th, then the options would expire worthless. If the stock was less than $5 on March 17th, the contract would be implimented, and I would be short 12,000 shares at $5 apiece. Most likely, I will try to sell the contracts for a profit before that happens so I won't have to deal with covering a short position.
High risk, though with limited downside, and high reward...though ving doesn't seem to get that, hi hi!
It can differ by stock but, in Synta's case, one put is a contract to sell 100 shares of stock. So one put contract cost me 100 times the per share price, or $20.
My 120 puts give me the right to sell 12,000 shares of Synta for $5 apiece on March 17th. With Synta closing trade price of $4.57, that means I can sell 12,0000 shares for 43 cents apiece more than it costs to buy them.
....could is the key word liz. Only a statsig phase III tells us the answer. The anecdotal examples are intriguing ....but I've seen positive examples before where the drug fails. Several times! That said....I am cautiosly optimistic. IF it works in tandem with crizotinib you are spot on. In the meantime...bios have lost some momentum....snta's track record thus far is less than stellar.....there are doubts re: a partnership...and with a high beta stock snta is extremely susceptible to a down market. ALL imho of course Best of luck.....barney
Let us all not forget that even if for some reason the two drugs ganetespib and crizotinib do not work together. WE still have our drug ganetespib which with our trails already has shown GREAT RESULTS. I maybe wrong but I believe the Company SNTA is a lot smarter than most here take them for. I still can not see Bruce Kovner,investing the Money he has Into SNTA if he did not see something. There are hundreds of stocks out there to invest in. Call me crazy but I am holding on to my shares, and probably am going to add more if the stock comes down anymore. Also remember that ganetespib is complementary to, rather than competitive with crizotinib.
What that means to me is that both drugs have a diffrent mechanism, both drugs are diffrent. Conclusion our dug there drug have had great results, TOGETHER they COULD be EXPLOSIVE. If those results would come back and they do work together then the stock would IMO MOVE UP QUICKLY. If they do not work togeather then we still have the GREAT results with ganetespib and the other drugs they have mathed it with.
Once again call me crazy but I see a WINNER here. Its now just a matter of time. Time is our only enemy here.
Always Do As You Feel, Not What You Hear